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Abstract: With continually improving treatment strategies and patient care, the overall mortality
of cardiovascular disease (CVD) has been significantly reduced. However, this success is a doubleedged sword, as many patients who survive cardiovascular complications will progress towards a
chronic disorder over time. A family of adiponectin paralogs designated as C1q complement/tumor
necrosis factor (TNF)-associated proteins (CTRPs) has been found to play a role in the development
of CVD. CTRPs, which are comprised of 15 members, CTRP1 to CTRP15, are secreted from different
organs/tissues and exhibit diverse functions, have attracted increasing attention because of their roles
in maintaining inner homeostasis by regulating metabolism, inflammation, and immune surveillance.
In particular, studies indicate that CTRPs participate in the progression of CVD, influencing its
prognosis. This review aims to improve understanding of the role of CTRPs in the cardiovascular
system by analyzing current knowledge. In particular, we examine the association of CTRPs with
endothelial cell dysfunction, inflammation, and diabetes, which are the basis for development of CVD.
Additionally, the recently emerged novel coronavirus (COVID-19), officially known as severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been found to trigger severe cardiovascular
injury in some patients, and evidence indicates that the mortality of COVID-19 is much higher in
patients with CVD than without CVD. Understanding the relationship of CTRPs and the SARS-CoV2-related damage to the cardiovascular system, as well as the potential mechanisms, will achieve a
profound insight into a therapeutic strategy to effectively control CVD and reduce the mortality rate.
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1. Introduction
Cardiovascular disease (CVD) is the leading global cause of death, accounting for 17.3
million deaths per year [1]. With the increase in the number of people with diabetes, the
morbidity and mortality of CVD are excessively accelerated [2,3].
A comprehensive understanding of the relationship between CVD and its risk factors
is of great interest in the research community. Recently, a family of C1q complement/tumor
necrosis factor (TNF)-associated proteins (CTRPs) has received attention due to their
newly discovered role in the cardiovascular system. CTRPs possess broad distribution,
participate in multiple aspects of metabolism, and potentiate regulation of homeostasis, and
hold potential as diagnostic or therapeutic targets of obesity-related metabolic disorders,
including CVD. Unraveling the signaling pathways downstream of CTRP family members
will facilitate new insights into therapeutic strategies for CVD.
CTRPs are also of interest in relation to COVID-19, the global pandemic evolving in
real time. A growing number of clinical reports indicate that obesity/diabetes is a risk
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activating the PI3K/Akt/eNOS pathway [12]. Inflammation plays a key part in atherosclero‐
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of the arterial
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underlying cause of CVD. The origin of atherosclerosis is related to lipid metabolism alterations, chronic inflammation, and oxidative stress. Many studies have demonstrated that
several CTRPs are involved in regulating the pathophysiological progression of atherosclerosis [21,22]. In particular, current research indicates that various CTRPs are involved in
the development and progression of atherosclerosis by regulating inflammation response,
lipid metabolism, and vascular smooth muscle cell (VSMC) proliferation [23–25].
CTRP1 reduces VSMC growth through the cAMP-dependent pathway to prevent
the development of pathological vascular remodeling [26]. Compared to a control group,
patients with severe coronary artery disease (CAD) had higher levels of CTRP1 in sera, coro-
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nary endarterectomy samples, atherosclerotic plaques, and peripheral blood mononuclear
cells (PBMCs) [27]. CTRP1 increases the expression of adhesion molecules and inflammatory cytokine through the p38 MAPK/NF-kB pathway, thereby promoting leucocyte
adhesion to endothelial cells in vitro and in vivo, suggesting that CTRP1 is an adipokine
contributing to atherogenesis [27]. However, which CTRP1-expressing cell type contributes
to promoting atherosclerosis and whether treatments targeting CTRP1 will prevent further
progression of established atherosclerosis and induce plaque regression have not been
confirmed. Further research is required.
In addition to CTRP1, CTRP3, CTRP6, and CTRP12, are involved in the regulation
of metabolism. They balance glucose levels by suppressing hepatic gluconeogenesis and
glucose output [28]. CTRP3 acts as lipopolysaccharide (LPS) antagonist of the adipose
tissue to block the proinflammatory activation of adipocytes and monocytes. It does so by
inhibiting three basic and common proinflammatory pathways: it inhibits the release of
chemokines in monocytes and adipocytes; it inhibits monocyte chemoattractant protein-1
release in adipocytes; it inhibits the binding of LPS to its receptor, TLR4/MD-2 [29]. CTRP6
mediates fatty acid oxidation via the AMPK-ACC pathway [30]. CTRP12, an adipokine
with antidiabetic actions, preferentially acts on adipose tissue and liver to control whole
body glucose metabolism [31]. CTRP12 have been found to be related to several CAD risk
factors, including BMI, inflammatory cytokines, insulin resistance, high-density lipoproteincholesterol, and adiponectin [32]. This result suggests a possible link between CTRP12 and
pathogenic mechanisms of atherosclerosis [32]. Endogenous CTRP12 protects against the
development of pathological vascular remodeling by attenuating macrophage inflammatory
responses and VSMC proliferation through transforming the growth factor-β receptor
II (TGF-βRII)/Smad2-dependent pathway in an established mouse model of vascular
injury [33]. In addition, the TGF-β1/Smad signaling pathway is responsible for vascular
fibrosis during the development of atherosclerosis [34]. Thus, it is necessary to further
investigate whether CTRP12 promotes vascular disease by increasing arterial fibrosis.
In regard to CTRP regulation in inflammatory response, in addition to CTRP1, CTRP5
promotes inflammation, proliferation, and migration in vascular smooth muscle cells
through activation of Notch1, TGF-β, and hedgehog signaling pathways [35]. CTRP6
stimulates expression of IL-10, an anti-inflammatory cytokine, in macrophages through
activating extracellular signal-regulated kinase1/2 (ERK1/2) [36]. In addition, CTRP6
inhibits platelet-derived growth factor-BB (PDGF-BB)-induced VSMC proliferation and
migration, partially, via suppression of the PI3K/Akt/mTOR signaling pathway [37]. The
above results suggest that CTRP5 and CTRP6 may be a potential target for the treatment
of atherosclerosis through regulating inflammatory responses and the proliferation and
migration of VSMC. Additionally, there are reports suggesting that serum CTRP5 levels
were higher in in-stent restenosis (ISR) patients than in non-ISR patients after drug-eluting
stent (DES)-based percutaneous coronary intervention (PCI) [35].
Although CTRP9 has been called cardiokine due to its high levels in the cardiac
system, it alters the components of carotid plaque and decreases inflammatory cytokines
in atherosclerotic plaque both in vivo and in vitro. As a result, CTRP9 may enhance
carotid plaque stability and play an anti-inflammation role against atherosclerosis [38].
CTRP9 reduces the inflammatory response to oxidized low-density lipoprotein in cultured
macrophages via an AMPK-dependent mechanism [39]. CTRP9 prevents VSMC proliferation and neointimal thickening following mechanical arterial injury [23]. Of importance, the
antiproliferative effects of CTRP9 are attributed to reduced ERK activation that is involved
in the cAMP-PKA regulatory axis [23]. CTRP9 slows the pathological progression of early
atherosclerosis by promoting cholesterol efflux to reduce the formation of foam cells, and
the AMPK/mTOR autophagy signaling pathway is a response to regulate this process [40].
CTRP9 has also shown atheroprotective function via the CTRP9-AMPK-NLR family pyrin
domain containing 3 (NLRP3) inflammasome pathway [41]. These studies indicate CTRP9
may play an antiatherogenic role. CTRP9 possesses vascular protective effects and involves
multiple signaling pathways to modulate the inflammatory response in the cardiovascular
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the secretion of inflammatory cytokines (e.g., MCP-1, TNF-a, IL-1β), thus promoting the
development of atherosclerosis [22]. CTRP9 might be important in the regulation of arterial
stiffness in humans based on findings that serum CTRP9 concentration is significantly
and positively associated with arterial stiffness in T2DM patients [49]. In T2DM and
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Although
the rolesDiseases
of CTRPs in the modulation of diabetic vascular disease are indirect,
4. CTRPs
and Cardiac
the direct roles in favor of decelerated diabetic vascular disease are still under exploration
Growing evidence has confirmed that CTRPs exerts crucial effects on cardioprotec‐
until the publication in 2020 [21], with the aim of demonstrating how globular CTRP5 (gCtion aspects through anti‐inflammation, antiapoptosis, antifibrosis, and proangiogenesis.
TRP5) directly influences on diabetic vascular disease. gCTRP5 is accumulated in diabetic
circulatory systems and appears to contribute to diabetic vascular EC dysfunction through
4.1. CTRPs and Heart Failure
Nox1-mediated mitochondrial apoptosis. gCTRP is one of the signaling molecules (along
with HFD and HGHL) that commonly activates expression of Nox1, which is implicated
in the pathogenesis of cardiovascular diseases. Research reasoned that gCTRP5 activates
the mitochondrial apoptotic signal of EC in diabetes, which is blocked by the silencing
Nox1 gene [21]. This study’s authors suggest that interventions blocking gCTRP5 may
protect diabetic EC function, ultimately protecting against diabetic cardiovascular complications [21]. Pharmacological interventions targeting CTRP5 or its related signaling may
provide promising therapeutic avenues to attenuate the development of atherosclerosis
or diabetic EC dysfunction and cardiovascular complications. To date, the role of CTRP5
in cardiac diseases is still unclear, but the above studies provide evidence for its potential
direct role in diabetic various cardiac diseases and so on.
The relationship of CTRPs with diabetes is more complex than expected. According
to clinical research data, CTRPs are responsible for the majority of the changes that occur
at the different levels of diabetes, including insulin resistance. Whether CTRPs can serve as
diagnostic or prognostic markers and a full view of the role of CTRPs in diabetes need to
be further investigated and discussed.
4. CTRPs and Cardiac Diseases
Growing evidence has confirmed that CTRPs exerts crucial effects on cardioprotection
aspects through anti-inflammation, antiapoptosis, antifibrosis, and proangiogenesis.
4.1. CTRPs and Heart Failure
Cardiac hypertrophy is an adaptive response to maintain cardiac function, but it
ultimately becomes mainly maladaptive and leads to heart failure (HF). However, accumulated data provided evidence that CTRPs are highly associated with cardiometabolics,
inflammatory response, and immunoregulatory function [53–55].
CTRP3 expression is upregulated in hypertrophic and failing hearts in murine models [56]. CTRP3 also promotes pressure overload-induced cardiac hypertrophy via acti-
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border zone revascularization [60]. Furthermore, by promoting cardiomyocyte–endothelial
farct border zone revascularization [60]. Furthermore, by promoting cardiomyocyte–endo‐
cell communication involving Akt-HIF1α-VEGF signaling, CTRP3 exerts an angiogenic
thelial cell communication involving Akt‐HIF1α‐VEGF signaling, CTRP3 exerts an angio‐
effect [60]. CTRP3 further exerts a cardiac antifibrotic effect post-MI by inhibiting myofibrobgenic effect [60]. CTRP3 further exerts a cardiac antifibrotic effect post‐MI by inhibiting my‐
last differentiation and the subsequent extracellular matrix production. AMPK is required
ofibroblast differentiation and the subsequent extracellular matrix production. AMPK is re‐
for the protective effect of CTRP3 against TGF-β1-induced profibrotic response. The effect
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effect of CTRP3 may be achieved by targeting the Smad3 signaling pathway [61] (Figure 3).
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pro‐
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and
Akt
activation
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the protective effect of CTRP6 against TGF-β1-induced fibrotic response by targeting the
Smad-independent myocardin-related transcription factor-A (RhoA/MRTF-A) signaling
pathway [62]. At present, there are no reports on the effects of CTRP6 on cardiomyocyte
apoptosis and angiogenesis post-MI. Further study is needed on the effects of CTRP6 and its
potential mechanisms. Recently, research has found that CTRP12 also ameliorates pathological remodeling of myocardium after MI by reducing myocardial inflammatory response
and apoptosis in vivo [63]. Furthermore, CTRP12 reduces inflammatory response and
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apoptosis of cardiomyocytes through the PI3 kinase/Akt signaling pathway [63]. CTRP15,
which is expressed abundantly in skeletal muscle and to a lesser extent in the lung, eye,
Proteomes 2021, 9, x FOR PEER REVIEW
9 of 16
smooth muscle, heart, and brain, exerts multiple biological effects, including promoting
lipid metabolism in hepatocytes and adipocytes, suppressing autophagy in the liver, and
modulating erythropoiesis [64–68]. CTRP15 is also known as myonectin [69]. Studies have
found
that CTRP15
inhibits the fibrotic
response
through
attenuating
myofibroblast
differand upregulates
interleukin‐10
in 3 days
post‐MI
to ameliorate
macrophage
infiltration
entiation
and
expression
of
profibrotic
molecules
on
pressure
overload-induced
cardiac
and inflammatory responses; it reduces the expressions of collagen types I and III, a‐SMA,
remodeling. The beneficial effects of CTRP15 on the TGF-β1-induced fibrotic response is
and transforming growth factor β1 in 7 days post‐MI by depressing the Toll‐like receptor
through the IR/IRS-1/PI3K/Akt pathway. Smad3 also participates in this CTRP50 s role [70].
4/nuclear factor‐kβ and Smad2/3 signaling pathway, thus playing an antifibrotic role in
CTRP15 suppresses cardiomyocyte apoptosis and macrophage inflammatory response
the left atrium; CTRP9 ameliorates vulnerability to atrial fibrillation in post‐MI rats [75];
through the S1P-dependent activation of the cAMP/Akt pathway in the heart, thereby
it can epigenetically modulate microRNAs to adjust the genes expression. Nevertheless,
ameliorating acute myocardial ischemic injury [71]. The receptor involved in mediating
it is unclear whether CTRP9 can reverse pathological immunoresponses and remodeling
these signaling pathways in cardiovascular tissues is not known and needs to be clarified
that have already developed. Clarification of this issue will require screening out a more
in future studies (Figure 6).
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in DC.treatment
(Figure 7)significantly decreases matrix
metalloproteinase2/matrix metalloproteinase 9 (MMP2/MMP9) activity and TGF-β1 production, the two most significant mechanisms contributing to post-MI fibrosis [73]. CTRP9
treatment also dramatically attenuates apoptotic cell death and significantly suppresses
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interstitial fibrosis [73]. Collectively, CTRP9 prevents left ventricle (LV) remodeling by
reducing apoptosis and fibrosis, and this occurs largely via a PKA-dependent pathway [73].
Studies in chronic intermittent hypoxia (MI+CIH) animals found that CTRP9 attenuates
interstitial fibrosis, improves cardiac function, and enhances survival rate via inhibiting
TGF-β/Smad and Wnt/β-catenin pathways [74]. MI+CIH upregulates the expression
of miR-214-3p, which is the target of CTRP9 gene [74]. Altogether, MI+CIH suppresses
cardiac CTRP9 expression by upregulating miR-214-3p, and exacerbating post-MI remodeling [74]. These findings provide evidence that CTRP9 and its related signaling maybe
a novel therapeutic target in improving cardiac function and alleviating the heart failure
(HF) phenotype in MI patients with obstructive sleep apnea (OSA). CTRP9 contributes
to cardiac hypertrophy and failure during pressure overload in part through activating
the ERK5-GATA4 pathway [57]. In the above research regarding the role of CTRP9 on
remodeling post-MI, the CTRP9 was administered before or shortly after ischemia and
alleviated adverse cardiac remodeling. In general, CTRP9 plays an crucial role in attenuating atrial inflammation, fibrosis, and atrial fibrillation post-MI in the following ways:
it markedly downregulates inflammatory factors, interleukin-1β and interleukin-6, and
upregulates interleukin-10 in 3 days post-MI to ameliorate macrophage infiltration and
inflammatory responses; it reduces the expressions of collagen types I and III, a-SMA,
and transforming growth factor β1 in 7 days post-MI by depressing the Toll-like receptor
4/nuclear factor-kβ and Smad2/3 signaling pathway, thus playing an antifibrotic role in
the left atrium; CTRP9 ameliorates vulnerability to atrial fibrillation in post-MI rats [75];
it can epigenetically modulate microRNAs to adjust the genes expression. Nevertheless,
it is unclear whether CTRP9 can reverse pathological immunoresponses and remodeling
that have already developed. Clarification of this issue will require screening out a more
delayed interval for CTRP9 administration.
4.3. CTRPs and Diabetic Cardiomyopathy
Diabetic cardiomyopathy (DC) is a diabetes mellitus (DM)-induced pathophysiological
condition that can result in HF. DC is characterized by myocardial fibrosis, dysfunctional
remodeling, and associated diastolic and systolic dysfunctions, and eventually HF [76]. To
date, there are few studies on the role of CTRPs in DC. CTRP3 in the heart protects against
diabetes-related cardiac dysfunction, oxidative damage, inflammation, and cell death
in vivo. Moreover, the protective effect of CTRP3 is mediated by activation of AMPKα,
and CTRP3 activates AMPKα via the cAMP–EPAC–MEK–LKB1 pathways in vivo [77].
Its downregulation by TNF-α-initiated oxidative PPARγ suppression exacerbates cardiac
injury in diabetic hearts [14]. These limited results may provide some theoretical basis
for the role of CTRPs in DC. In addition to CTRP9, CTRP1, CTRP4, and CTRP7 are also
expressed in the heart at levels significantly greater than APN. However, the impact of
Proteomes 2021, 9, x FOR PEER REVIEW
of 16
these CTRPs on DC are unclear. Future studies should examine the roles of these10
CTRPs
and their underlying mechanisms in DC. (Figure 7)
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5. CTRPs and the Role in CVD Patients with COVID‐19
The outbreak of SARS‐Cov‐2 (Coronavirus Disease‐2019 (COVID‐19)) has been claim
a public health emergency of international concern [78]. Its effects include injury to the
cardiovascular system.
5.1. Role of COVID‐19 in Cardiovascular Injury
The genome of CoVs is a single stranded positive‐sense RNA, and SARS‐CoV‐2 con‐
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5. CTRPs and the Role in CVD Patients with COVID-19
The outbreak of SARS-Cov-2 (Coronavirus Disease-2019 (COVID-19)) has been claim
a public health emergency of international concern [78]. Its effects include injury to the
cardiovascular system.
5.1. Role of COVID-19 in Cardiovascular Injury
The genome of CoVs is a single stranded positive-sense RNA, and SARS-CoV-2 contains
four structural proteins (S, E, M, and N) and sixteen nonstructural proteins (nsp1-16) [79–82].
Angiotensin-converting enzyme 2 (ACE2) has been identified as a functional receptor
for SARS-CoV and SARS- CoV-2 [81,83,84]. Thus, the expression of ACE2 is a critical
determinant for the entry of the virus. ACE2 is a membrane-bound aminopeptidase that
exerts a key effect in the cardiovascular and immune systems [83,85,86]. Recently, further
research has identified ACE2 as highly expressed in pericytes of adult human hearts, [87] and
patients with basic heart failure disease exhibited increased expression of ACE2, suggesting
an intrinsic susceptibility of the heart to SARS-CoV-2 infection [87,88]. Clinical direct
evidence was provided in early studies in China, where 7–20% of patients with COVID-19
were observed with damage to the cardiac system [88–92]. In one study, 5 out of 41 COVID19 patients showed SARS-COV-2-related myocardial injury, mainly manifested by increased
levels of high-sensitivity cardiac troponin I (hs-cTnI) levels (>28 pg/mL) in Wuhan [88].
Therefore, in addition to causing respiratory damage, COVID-19 disease could also damage
the cardiovascular system [93,94].
In addition, myocardial injury and heart failure accounted for 40% of deaths in one
Wuhan cohort [95]. One study reported a 16.7% incidence of arrhythmia in 138 Chinese
COVID-19 patients [89]. Brain-type natriuretic peptide (BNP) levels were also elevated
in Washington ICU inpatients [96]. Thus, cardiac injury is prevalent in COVID-19 and
apparently impacts prognosis. However, the mechanism of COVID-19 caused cardiac injury
is unknown. Although accumulating data reveal elevated inflammatory cytokines levels
(including IL-2, IL-7, IL-10, granulocyte colony- stimulating factor (G-CSF), IP-10, MCP1,
macrophage inflammatory protein 1α (MIP1α) and TNF) and percentage of CD14+ CD16+
inflammatory monocytes in blood plasma of patients with severe COVID-19, [97] evidence
for whether these cause a storm of inflammation in the heart is lacking. The myocardial
injury may involve increased cardiac stress due to respiratory failure and hypoxemia;
indirect injury due to systemic inflammation; direct myocardial infection by SARS-COV-2;
or a combination of all three factors.
5.2. Diabetes in CVD Patients with COVID-19
Other than inflammation, a growing number of clinical reports indicate that obesity is
a risk factor for COVID-19 severity [4,98] and an adverse prognosis [97]. In COVID-19 infections, one notable feature of this disease is that the high prevalence of obese patients among
the most severe cases. Recent evidence indicates that obese states cause chronic low-grade
inflammation, which contributes to the development of CVD [5,99]. In obese state, the
secretion of proinflammatory adipokines, such as leptin, TNF-α, IL-6, and IL-1β, are upregulated, but anti-inflammatory adipokines are downregulated, especially adiponectin [5,99].
The chronic low-grade inflammation that contributes to the innate immune system might be
already in a “primed state” that could promote an hyperinflammatory response [100,101].
Thus, the obese state may amplify the proinflammatory response to SARS-CoV-2 infection
and induce more serious cardiovascular damage compared to the nonobese state [100,101].
In addition, two months after discharge from the hospital, 70% of patients with COVID-19
showed cardiac dysfunction and significant cardiac fibrosis. The TGF-β1/Smad3 pathway
may be involved in that process [102]. Varga et al. proved the presence of viral elements and
accumulation of inflammatory cells within endothelial cells of COVID-19 patients, [103]
which suggests that SARS-CoV-2 infection could cause endothelial dysfunction.
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5.3. CTRPs in Patients with COVID-19
Treatment for COVID-19 should give particular attention to cardiovascular protection,
especially in patients who have obesity or diabetes [104]. The mechanism of cardiovascular
injury caused by SARS- CoV-2 infection might be related to ACE2 and inflammatory
cytokine storms [105,106]. Numerous adipokines exert imbalanced expressions in the obese
or diabetes state, which leads to a series of inflammation response and cardiovascular
damage. Many studies have demonstrated that adiponectin plays a crucial role in antiinflammatory and cardiovascular protection [107]; however, adiponectin resistance is
present in obesity state and the expression level is downregulated in the diabetes state.
CTRPs share a common structural domain with adiponectin and some (e.g., CTRP3, CTRP9,
CTRP12) also exhibit anti-inflammatory and cardiovascular protective roles. Controlling
the inflammatory response via CTRPs may be a potential target for relieving cardiac injury
during treatment for COVID-19. Although current knowledge on CTRPs with COVID19 is largely unknown, in consideration of CTRPs’ roles in modulating cardiovascular
metabolism and preventing inflammatory response, the enhanced understanding and
potential use in clinical treatment of cardiaovascular injury of patients with COVID-19 are
promising.
6. Prospective
Although the discovery of new proteins is driven by cutting-edge techniques including
proteomics, the in-depth exploration of proteomics technology still need to broaden the
new insight/innovation on protein biological functions by improving the performances
of mass spectrometers. The newly discovered CTRP family plays an important role in
CVD not only by regulating immuno-inflammation, glucose and lipid metabolism, and
vascular endothelial function, but also by reducing cardiomyocyte apoptosis and fibrosis
and by ameliorating cardiac function. The CTRP family reveals an exciting avenue for CVD
therapeutics. CTRPs and their related signals hold potential to be used as biomarkers or
therapeutic interventions against cardiovascular disease, including in patients who have
been infected with COVID-19.
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